Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Laser-based Equipment, Microwave-based Equipment, Radiofrequency-based Equipment, Other), By End user (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 11.56 Billion
CAGR (2026-2031)	4.41%
Fastest Growing Segment	Laser based equipment
Largest Market	North America
Market Size (2031)	USD 14.98 Billion

Market Overview

The Global Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market will grow from USD 11.56 Billion in 2025 to USD 14.98 Billion by 2031 at a 4.41% CAGR. The Global Benign Prostatic Hyperplasia Treatment Equipment Market encompasses medical devices utilized for the minimally invasive and surgical management of enlarged prostate glands, such as resectoscopes, laser systems, and radiofrequency ablation devices. The primary drivers fueling market expansion include a rapidly aging global demographic and an increasing preference for minimally invasive procedures that ensure faster patient recovery. This growing demand is critically underpinned by the high incidence of the condition among elderly men. According to the American Urological Association, in 2024, the prevalence of benign prostatic hyperplasia and associated lower urinary tract symptoms among men aged 65 and older was reported to range between 29% and 35%.

Despite these favorable demand metrics, one significant challenge impeding broader market expansion is the high capital expenditure required for advanced surgical technologies. The substantial acquisition and maintenance costs of modern laser consoles and robotic systems can limit adoption rates, particularly in healthcare facilities operating with constrained procurement budgets. This financial barrier often forces providers in cost-sensitive regions to rely on traditional, less efficient methodologies, thereby slowing the penetration of newer equipment solutions.

Key Market Drivers

The escalating prevalence of benign prostatic hyperplasia is fundamentally driven by the rapid aging of the global male population, which necessitates a sustained increase in the deployment of diagnostic and therapeutic equipment. As life expectancy rises, the pool of patients requiring intervention for lower urinary tract symptoms expands, compelling healthcare providers to upgrade their urology departments. This demographic shift creates a predictable and growing addressable market for manufacturers of resectoscopes and ablation systems. According to the United Nations, July 2024, in the 'World Population Prospects 2024: Summary of Results', the share of the global population aged 65 years or older is projected to rise to nearly 16% by 2050, widening the primary demographic bracket susceptible to prostate enlargement.

Concurrent with demographic shifts, there is a marked surge in demand for minimally invasive and non-surgical treatment modalities, driven by patient preference for procedures that offer shorter recovery times. This trend forces the market toward advanced technologies such as robotic-assisted waterjet ablation and prostatic urethral lift devices, moving away from traditional transurethral resection. Consequently, companies specializing in these novel platforms are witnessing substantial adoption rates. According to PROCEPT BioRobotics, February 2024, in the 'Fourth Quarter and Full Year 2023 Financial Results', revenue for their robotic systems reached $136.2 million for the fiscal year 2023, marking an 82% increase compared to the previous year. This technological uptake is further validated by broader sector performance; according to Boston Scientific, in 2024, the Urology and Pelvic Health business segment achieved net sales of $1.95 billion for the full year 2023.

Download Free Sample Report

Key Market Challenges

Based on the provided overview, the significant challenge hampering the growth of the Global Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market is the high capital expenditure required for advanced surgical technologies.

The substantial acquisition and ongoing maintenance costs associated with modern laser consoles and robotic systems create a formidable financial barrier to adoption. Healthcare facilities, particularly those with constrained procurement budgets, must carefully evaluate the return on investment for such capital-intensive equipment. When the upfront cost of these devices is weighed against the financial realities of hospital operations, many providers are forced to defer purchasing decisions. This economic pressure compels institutions to continue relying on traditional, less expensive methodologies like transurethral resection, thereby stalling the market penetration of newer, more efficient equipment solutions.

This difficulty in justifying high-value acquisitions is further exacerbated by tightening reimbursement structures that reduce the available capital for reinvestment. According to the American Urological Association, in 2024, the Medicare Physician Fee Schedule conversion factor was reduced by approximately 3.37%, decreasing to $32.74 from the previous year. Such reductions in payment rates directly impact the revenue streams of urology practices and hospitals, significantly limiting their capacity to absorb the high costs of advanced BPH treatment systems and directly impeding market expansion.

Key Market Trends

The Integration of Artificial Intelligence in Robotic Aquablation Systems represents a transformative shift, moving procedural precision beyond human limitations. Manufacturers are embedding machine learning algorithms into robotic consoles to optimize treatment planning and real-time tissue resection. This technology utilizes vast datasets of anatomical imagery to assist surgeons in mapping prostate contours, enhancing safety and consistency during waterjet ablation. According to PROCEPT BioRobotics, August 2024, in the 'PROCEPT BioRobotics Announces FDA Clearance of the HYDROS Robotic System', the newly cleared AI-powered platform leverages insights from over 50,000 real-world procedures to deliver advanced image guidance and predictive workflows for benign prostatic hyperplasia treatment.

Simultaneously, the Commercialization of Temporary Implantable Nitinol Devices is reshaping minimally invasive therapies by offering symptom relief without permanent implants or thermal damage. These devices, which temporarily reshape the prostatic urethra, are gaining traction for their ability to preserve sexual function and allow rapid recovery in outpatient settings. Market players are aggressively securing contracts to ensure these solutions are accessible to healthcare providers and ambulatory centers. According to Olympus, March 2024, in the 'Olympus Announces iTind Treatment Milestone with Availability Through Major GPOs', the company's temporary nitinol device secured placement on 13 Group Purchasing Organization contracts in the United States, significantly expanding the commercial reach of this non-permanent therapeutic option.

Segmental Insights

The laser-based equipment segment represents the most rapidly expanding category within the global Benign Prostatic Hyperplasia treatment equipment market. This accelerated growth is primarily driven by the increasing demand for minimally invasive procedures that offer reduced recovery times and shorter hospital stays compared to traditional surgical methods. Furthermore, the rising adoption of these devices is supported by favorable safety profiles and continued clearances from regulatory authorities such as the U.S. FDA, which enhance clinical confidence. Consequently, healthcare providers are prioritizing laser therapies to minimize post-operative complications and improve overall patient management efficiency.

Regional Insights

North America maintains a dominant position in the global Benign Prostatic Hyperplasia Treatment Equipment market due to the rising prevalence of urological conditions among its aging population. This leadership is further supported by a well-established healthcare infrastructure that facilitates the widespread adoption of minimally invasive procedures. The robust regulatory framework provided by the U.S. Food and Drug Administration ensures the timely approval of new devices, while favorable reimbursement coverage from the Centers for Medicare and Medicaid Services enhances patient accessibility. Consequently, these factors collectively strengthen the regional market presence without relying on generic growth projections.

Recent Developments

• In August 2024, PROCEPT BioRobotics Corporation received 510(k) clearance from the U.S. Food and Drug Administration for its next-generation surgical platform, the HYDROS Robotic System. This advanced system integrates artificial intelligence-powered treatment planning, high-definition image guidance, and robotic resection to deliver Aquablation therapy for benign prostatic hyperplasia. Designed to streamline surgical workflows and improve clinical efficiency, the platform utilizes real-time ultrasound and cystoscopy imaging to allow surgeons to map and remove obstructive tissue with precision. The clearance marks a pivotal expansion for the company, aiming to increase the adoption of its robotic therapy in hospitals across the United States.
• In May 2024, Laborie Medical Technologies Corp. unveiled positive long-term clinical data for its Optilume BPH Catheter System during the American Urological Association Annual Meeting. The company presented two-year results from the PINNACLE study and five-year results from the EVEREST study, demonstrating sustained symptomatic relief and improved urinary flow rates. The Optilume system, a drug-device combination therapy that pairs mechanical dilation with localized drug delivery, showed a durable reduction in the International Prostate Symptom Score without negatively impacting sexual function. These findings reinforce the efficacy of this minimally invasive surgical therapy as a safe alternative for patients suffering from lower urinary tract symptoms.
• In April 2024, Teleflex Incorporated announced the full market release of a new advancement for its minimally invasive benign prostatic hyperplasia treatment portfolio. The company introduced the UroLift 2 System with Advanced Tissue Control, which received clearance from the U.S. Food and Drug Administration. This unified platform features adaptable design elements, including tissue control wings and laser-etched markers, to provide physicians with enhanced confidence and precision during procedures. The system is designed to treat a wide range of prostate anatomies, including those with median lobe obstruction, offering a streamlined delivery mechanism that improves efficiency for urologists treating men with enlarged prostates.
• In March 2024, Olympus Corporation announced a significant commercial milestone for its benign prostatic hyperplasia treatment device, the iTind procedure. The company secured availability for the device through contracts with major healthcare group purchasing organizations in the United States, expanding patient access to this minimally invasive solution. This development allows a broader range of hospitals and ambulatory surgical centers to procure the temporary nitinol device, which reshapes the prostatic urethra without permanent implantation or tissue removal. The expansion into these purchasing networks reflects the growing adoption of non-surgical options for relieving lower urinary tract symptoms associated with an enlarged prostate.

Key Market Players

• Urologix, LLC
• Olympus Corporation
• Boston Scientific Corporation
• Teleflex Incorporated
• Zenflow Inc.
• Sonablate Corporation
• Richard Wolf Gmbh
• Karl Storz SE
• Terumo Medical Corporation

By Type	By End user	By Region
Laser-based Equipment Microwave-based Equipment Radiofrequency-based Equipment Other	Hospitals & Clinics Ambulatory Care Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market, By Type:

• Laser-based Equipment
• Microwave-based Equipment
• Radiofrequency-based Equipment
• Other

• Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market, By End user:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

• Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE